Boehringer Ingelheim completes $228M biologics facility expansion in Fremont

Boehringer Ingelheim completed the expansion of its biopharmaceutical manufacturing facility in Fremont, California, with a $228 million investment over two years, creating 300 new jobs and increasing worldwide bioreactor capacity to 290,000 liters.

“The company announced that it was now well-positioned to manufacture future biopharmaceutical medicines, both from its own research pipeline and as a contract manufacturer for other pharmaceutical and biopharmaceutical companies.”process-worldwide.com

• 1 source
• process-worldwide.comBoehringer Ingelheim Completes Expansion of Biologics ProductionEditor: Alexander StarkNov 1, 2018

Summarized from public sources; check the original articles before acting on it.